Jason Aryeh
CIK 1376960 · last filed 2026-11-03
Jason Aryeh is a corporate insider who has filed 182 SEC Form 4 insider transactions across 11 companies since 2007. The most recent filing, for LGND, was dated Nov 4, 2026. Across all open-market trades the lifetime net is −$34.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $52.2M across reported positions. 77 SEC filings were submitted jointly with LIGAND PHARMACEUTICALS INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
LGND price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 200
LA JOLLA, CA 92037
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LGND | Director | 117,508 | $306.75 | $36.05M | -$32.49M | 68 | 2026-11-03 |
| OBIO | Director | 118,118 | $5.70 | $673.3K | $39.9K | 13 | 2026-06-25 |
| LFCR | Director | 69,967 | $6.37 | $445.3K | $0 | 3 | 2026-06-05 |
| Anebulo Pharmaceuticals, Inc. (ANEB) Delisted | Director | — | $0.36 | — | $0 | 3 | 2025-04-07 |
| MERRIMACK PHARMACEUTICALS INC (MACK) Delisted | 10%+ Owner | 3,802 | $15.13 | $57.5K | $21.5K | 2 | 2019-07-18 |
| Aralez Pharmaceuticals Inc. (ARLZ) Delisted | Director | 15,000 | — | — | $1.17M | 4 | 2017-05-24 |
| NOVELION THERAPEUTICS INC. (NVLN) Delisted | Director | 369,924 | — | — | $3.2K | 2 | 2017-05-17 |
| IMMUNOMEDICS INC (IMMU) Delisted | Director | — | — | — | $0 | 1 | 2017-01-10 |
| QLTI | Director | 535,478 | $28.00 | $15.00M | $1.05M | 18 | 2016-06-21 |
| Myrexis, Inc. (MYRX) Delisted | Director | 9,900 | — | — | $1.15M | 19 | 2012-06-20 |
| Vaxart, Inc. (NABI) Delisted | Director | 21,964 | — | — | -$5.87M | 39 | 2011-05-27 |
Recent Filings
182 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-11-04 | LGND | Notice (144) | −282 | -$90.2K | EDGAR |
| 2026-11-03 | LGND | Sell (S) | −2,111 | -$676.2K | EDGAR |
| 2026-11-02 | LGND | Notice (144) | −700 | -$221.6K | EDGAR |
| 2026-10-30 | LGND | Notice (144) | −1,209 | -$385.2K | EDGAR |
| 2026-10-30 | LGND | Notice (144) | −202 | -$64.7K | EDGAR |
| 2026-06-25 | OBIO | Grant (A) | — | $0 | EDGAR |
| 2026-06-12 | LGND | Mixed | −4,164 | -$1.25M | EDGAR |
| 2026-06-11 | LGND | Notice (144) | −4,500 | -$1.12M | EDGAR |
| 2026-06-10 | LGND | Notice (144) | −500 | -$125.0K | EDGAR |
| 2026-06-10 | LGND | Notice (144) | −5,000 | -$1.25M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.